Elizabeth Jungman directs Pew’s work on drug safety and innovation, overseeing Pew’s initiatives related to antibiotics and innovation, drug safety, and prescription drug abuse. Before joining Pew, she served as a senior health policy adviser with the Senate Committee on Health, Education, Labor, and Pensions, where she played a key role in drafting and negotiating the Food and Drug Administration Safety and Innovation Act of 2012, the FDA provisions in the Pandemic All-Hazards Preparedness Reauthorization Act of 2013, and the Drug Quality and Security Act of 2013, which included drug compounding and supply chain security measures. Before moving to the Hill, Jungman was in private legal practice, where she counseled clients on a broad range of FDA regulatory matters and other health care issues related to the human pharmaceutical industry. She has an undergraduate biology degree from Harvard College, a J.D. from Georgetown University, and a master’s degree in public health from Johns Hopkins University.
Recent WorkView All
On September 19, Allan Coukell, senior director of drugs and medical devices testified, delivered testimony in front of the House Committee on Energy and Commerce Health Subcommittee at a hearing entitled “Examining Ways to Combat Antibiotic Resistance and Foster New Drug Development." Read More
The Obama administration laid out a national strategy today to stem the rising tide of antibiotic resistance, which threatens human health worldwide. The strategy provides an opportunity to bring together the resources of the federal government, agency-by-agency, to address this mounting crisis. Read More
The Drug Supply Chain Security Act (DSCSA) of 2013 created a national system in which companies involved in pharmaceutical distribution work together to safeguard the U.S. pharmaceutical supply and protect consumers from compromised or counterfeit drugs. Pharmacies play a critical role in preventing unsafe products from reaching consumers. Read More